Hexamethylmelamine in ovarian cancer resistant to cyclophosphamide and adriamycin

G. Bolis, M. D'Incalci, C. Belloni, C. Mangioni

Research output: Contribution to journalArticlepeer-review

Abstract

Thirty-four patients resistant to cyclophosphamide and Adriamycin received hexamethylmelamine at one of two dose regimens: 6 mg/kg/day orally for 21 days every 4 weeks or 8 mg/kg/day orally for 21 days every 6 weeks. Only five patients responded. Tolerance to the drug was, however, satisfactory; nausea, pyrosis, and vomiting were the only frequent side effects. Myelosuppression occurred in only one case.

Original languageEnglish
Pages (from-to)1375-1377
Number of pages3
JournalCancer Treatment Reports
Volume63
Issue number8
Publication statusPublished - 1979

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Hexamethylmelamine in ovarian cancer resistant to cyclophosphamide and adriamycin'. Together they form a unique fingerprint.

Cite this